[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n BcDwdGpKgnwH9i/cWc/4e52XPuYIwWQ3ktvdr6p8sP7ks7XrqGszG0VtlcnPvcV4\n gSaVR14jpoFSNiPTSOzSUw==\n\n', u'0001104659-04-028380.txt : 20040923\n', u'0001104659-04-028380.hdr.sgml : 20040923\n', u'20040923171710\nACCESSION NUMBER:\t\t0001104659-04-028380\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t3\nCONFORMED PERIOD OF REPORT:\t20040921\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20040923\nDATE AS OF CHANGE:\t\t20040923\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tNORTH AMERICAN SCIENTIFIC INC\n\t\tCENTRAL INDEX KEY:\t\t\t0000949876\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]\n\t\tIRS NUMBER:\t\t\t\t954283918\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t1031\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t000-26670\n\t\tFILM NUMBER:\t\t041043316\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t20200 SUNBURST ST\n\t\tCITY:\t\t\tCHATSWORTH\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t91311\n\t\tBUSINESS PHONE:\t\t8187348600\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t20200 SUNBURST ST\n\t\tCITY:\t\t\tCHATSWORTH\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t91311\n', u'\n', u'\n', u'8-K\n', u'1\n', u'a04-10829_18k.htm\n', u'8-K\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'UNITED\nSTATES', u'\nSECURITIES AND EXCHANGE COMMISSION', u'\n', u'Washington, D.C. 20549', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'FORM\n8-K', u'\n', u'\xa0', u'\n', u'CURRENT\nREPORT PURSUANT TO SECTION 13 OR 15(d)', u'\n', u'OF THE\nSECURITIES EXCHANGE ACT OF 1934', u'\n', u'\xa0', u'\n', u'September 21, 2004', u'Date of Report (Date of earliest event\nreported)', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'NORTH AMERICAN SCIENTIFIC, INC.', u'\n', u'(Exact name of registrant\nas specified in its charter)', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'Delaware', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'0-26670', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'51-0366422', u'\n', u'\n', u'\n', u'\n', u'\n', u'(State or other\n  jurisdiction of', u'\n  incorporation)', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(Commission', u'\n  File Number)', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(I.R.S. Employer', u'\n  Identification No.)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'20200 Sunburst Street, Chatsworth, California 91311', u'\n', u'\n', u'\n', u'\n', u'\n', u'(Address of principal executive\n  offices)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0(Zip\n  Code)', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(818)\n734-8600', u'\n', u'(Registrant\x92s telephone number, including\narea code)', u'\n', u'\xa0', u'\n', u'Not\nApplicable', u'\n', u'(Former Name or Former Address, if Changed\nSince Last Report)', u'\n', u'\xa0', u'\n', u'Check the appropriate box\nbelow if the Form 8-K filing is intended to simultaneously satisfy the filing\nobligation of the registrant under any of the following provisions:', u'\n', u'\xa0', u'\n', u'o', u' Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)', u'\n', u'\xa0', u'\n', u'o', u' Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)', u'\n', u'\xa0', u'\n', u'o', u' Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR\n240.14d-2(b))', u'\n', u'\xa0', u'\n', u'o', u' Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR\n240.13e-4(c))', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='',FILE='C:\\jms\\ssounda\\04-10829-1\\task187564\\10829-1-ba.htm',USER='ssoundarrajan',CD='Sep 23 01:45 2004' ", u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Item 2.02.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 Results\nof Operations and Financial Condition.', u'\n', u'\xa0', u'\n', u'On September 21, 2004, North\nAmerican Scientific, Inc. issued a press release announcing its results of\noperations for the quarter ended July 31, 2004.\xa0 A copy of the press release is attached hereto as Exhibit 99.1.', u'\n', u'\xa0', u'\n', u'The information in this current\nreport on Form 8-K and the exhibit attached hereto shall not be deemed to be\n\x93filed\x94 for the purposes of Section 18 of the Securities Exchange Act of 1934,\nnor shall it be deemed incorporated by reference into any filing made under the\nSecurities Act of 1933, except as expressly set forth by specific reference in\nsuch filing.', u'\n', u'\xa0', u'\n', u'Item 9.01.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 Financial\nStatements and Exhibits', u'\n', u'\xa0', u'\n', u'(c)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 Exhibits', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'Exhibit No.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Description', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Exhibit 99.1', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Press\n  Release of North American Scientific, Inc. dated September 21, 2004.', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'2', u'\n', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='2',FILE='C:\\jms\\ssounda\\04-10829-1\\task187564\\10829-1-ba.htm',USER='ssoundarrajan',CD='Sep 23 01:45 2004' ", u'\n', u'\n', u'\n', u'\xa0', u'\n', u'SIGNATURES', u'\n', u'\xa0', u'\n', u'Pursuant to\nthe requirements of the Securities Exchange Act of 1934, the Registrant has\nduly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'NORTH\n  AMERICAN SCIENTIFIC, INC.', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Date:', u'\n', u'\n', u'\n', u'September\n  21, 2004', u'\n', u'\n', u'\n', u'By:', u'\n', u'\n', u'\n', u'/s/ L.\n  Michael Cutrer', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Name:', u'\n', u'\n', u'\n', u'L. Michael\n  Cutrer', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Title:', u'\n', u'\n', u'\n', u'President\n  and', u'\n  Chief Executive Officer', u'\n  (Principal Executive Officer)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'3', u'\n', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='3',FILE='C:\\jms\\ssounda\\04-10829-1\\task187564\\10829-1-ba.htm',USER='ssoundarrajan',CD='Sep 23 01:45 2004' ", u'\n', u'\n', u'\n', u'\xa0', u'\n', u'EXHIBIT INDEX', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'Exhibit No.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Description', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Exhibit 99.1', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'North\n  American Scientific, Inc. press release dated September 21, 2004.', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'4', u'\n', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='4',FILE='C:\\jms\\ssounda\\04-10829-1\\task187564\\10829-1-ba.htm',USER='ssoundarrajan',CD='Sep 23 01:45 2004' ", u'\n', u'\n', u'\n', u'\n', u'EX-99.1\n', u'2\n', u'a04-10829_1ex99d1.htm\n', u'EX-99.1\n', u'\n', u'\n', u'EXHIBIT 99.1', u'\n', u'\xa0', u'\n', u'FOR IMMEDIATE RELEASE', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'At the Company', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'At CCG Investor Relations', u'\n', u'\n', u'\n', u'\n', u'\n', u'Contact: Jim Klingler, CFO', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Contact: Sean Collins, Partner', u'\n', u'\n', u'\n', u'\n', u'\n', u'Phone: (818) 734-8600', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Phone: (818) 789-0100', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'NORTH AMERICAN SCIENTIFIC REPORTS THIRD QUARTER FINANCIAL\nRESULTS', u'\n', u'\xa0', u'\n', u'\x95', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 ', u'Company achieves record revenue\nof $8.1 million.', u'\n', u'\xa0', u'\n', u'\x95', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 ', u'Company adopts SOP 97-2 revenue\nrecognition accounting policy for products acquired in NOMOS acquisition, and\ndefers $1.2 million in revenue to subsequent periods.', u'\n', u'\xa0', u'\n', u'Chatsworth, CA \x96', u' ', u'September 21, 2004', u' \x97', u' North American Scientific, Inc. (Nasdaq: NASI)\ntoday announced financial results for its third quarter ended July 31, 2004.', u'\n', u'\xa0', u'\n', u'For\nthe third quarter ended July 31, 2004, the Company reported record net sales of\napproximately $8.1 million, as compared with net sales of $3.0 million for the\nthird quarter of 2003.\xa0 Management\nattributed the increase in sales primarily to the consolidation of the NOMOS\nacquisition, which was completed on May 4, 2004.\xa0 ', u'Net', u' ', u'sales\nby operating segment in the third quarter of 2004 included $3.1 million of\nRadiation Sources (brachytherapy and other radioisotope-based products), which\nincreased 3% over the corresponding period last year, and $5.0 million of\nIMRT/IGRT products.\xa0 The Company\x92s\nresults reflect its decision to adopt the revenue recognition policy under SOP\n(Statement of Position) 97-2 with respect to sales of its BAT\xae (B-Mode\nAcquisition and Targeting System) products whereby sales are recognized upon\nproduct acceptance by the customers rather than at the time of shipment. This\nresulted in approximately $1.2 million in revenue being deferred to subsequent\nperiods.', u'\n', u'\xa0', u'\n', u'The net loss for the third\nquarter of 2004 was $19.4 million, or $1.24 per share, and included $13.5\nmillion, or $0.86 per share, of the following non-recurring expenses: $7.8\nmillion for the write-off of in-process R&D included in the purchase of\nNOMOS, $1.0 million of integration expenses and a non-cash impairment charge of\n$4.7 million to write-off the goodwill and other assets of its Theseus subsidiary.\nThis compared to a net loss for the third quarter of 2003 of $2.8 million, or\n$0.28 per share.', u'\n', u'\xa0', u'\n', u'At July 31, 2004, the\nCompany\x92s cash, cash equivalents and marketable securities totaled $23.1\nmillion. ', u'\n', u'\xa0', u'\n', u'L.\nMichael Cutrer, President and CEO, commented, \x93The integration of the NOMOS\noperations continues, and I am pleased with the progress we are making.\xa0 Since the close of the quarter, we have been\npleased to see two positive developments in connection with the intensity-modulated\nradiation therapy (IMRT) and image guided radiation therapy (IGRT) products\nthat', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='',FILE='C:\\JMS\\eudelhofen\\04-10829-1\\task187972\\10829-1-mm.htm',USER='eudelho',CD='Sep 23 13:08 2004' ", u'\n', u'\n', u'\xa0', u'\n', u'we\nhave added to our product portfolio through the NOMOS acquisition.\xa0 The first was our completion of an agreement\nwith Elekta that will allow for more aggressive radiation-based cancer\ntreatment, combining Elekta\x92s digital linear accelerators and our BAT\nimage-guided ultrasound technology.\xa0 The\nsecond was the launch of an IGRT optical camera targeting solution, which\nexpands clinical applications for our innovative BAT', u'\xae', u' tumor imaging systems.\xa0 Our products for IMRT enhance the life-saving\nreach, power and sensitivity of radiation treatment and provide us with\nworldwide markets where our further technological innovations and refinements\ncan have a significant impact.', u'\n', u'\xa0', u'\n', u'Mr.\nCutrer went on to state, "As we announced in our quarterly reports filed\nwith the SEC, our independent registered public accounting firm has not yet\ncompleted their review of our interim financial statements for the quarter\nended July 31. 2004.\xa0 However, we felt it\nwas important not to further delay the filing and the release of our quarterly\nfinancial results."', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0&\n#160;\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 ', u'\n', u'Theseus Imaging Subsidiary', u'\n', u'\xa0', u'\n', u'Recently, the\nCompany announced that it intends to terminate operations at its Theseus\nImaging subsidiary in Boston and Worcester, Massachusetts on September 15,\n2004.', u'\n', u'\xa0', u'\n', u'The Company\nintends to redirect some of the approximately $10 million it projected to spend\non the Hynic-Annexin V program in fiscal 2005 to other product development\nopportunities, with particular focus on its intensity modulated radiation\ntherapy (IMRT) and image guided radiation therapy (IGRT) products. ', u'\n', u'\xa0', u'\n', u'Costs stemming\nfrom the termination of the Theseus Imaging subsidiary are expected to be\napproximately $6.0 million, including $4.8 million in non-cash charges to write\noff the assets of Theseus (which were taken in the fiscal third quarter as\ndiscussed above) and $1.2 million in severance and shut-down expenses.', u'\n', u'\xa0', u'\n', u'The Company\nintends to temporarily maintain the clinical trial data, intellectual property\ndeveloped during the program and the existing GMP Annexin material until\nOctober 31, 2004 , in an effort to assist companies that may be interested in\npurchasing the assets of the program.', u'\n', u'\xa0', u'\n', u'A conference call will be scheduled when the\nCompany\x92s independent registered public accounting firm has completed their\nreview of the financial statements for the quarterly period ending July 31,\n2004.', u'\n', u'\xa0', u'\n', u'About North American Scientific', u'\n', u'\xa0', u'\n', u'North American Scientific is a\nleader in products for radiation therapy.\xa0\nIts innovative radioisotope-based products include brachytherapy seeds,\nused primarily in the treatment of prostate cancer, marketed under the trade\nname Prospera', u'\xae', u'.\xa0 The Company is also a leading\nsupplier of planning and delivery technology for intensity modulated radiation\ntherapy (IMRT) and image guided radiation therapy (IGRT). IMRT allows an\nescalated radiation dose to be delivered to a tumor while limiting exposure and\ndamage to nearby healthy tissue.\xa0 The\nCompany\x92s principal IMRT products are marketed under the trade names PEACOCK', u'\xae', u' and CORVUS', u'\xae', u'.\xa0 The\nCompany\x92s IGRT product, BAT', u'\xae', u', provides fast and accurate targeting and localization of a treatment\nvolume on a daily basis.\xa0 More than 400\nhospitals and research sites worldwide are equipped with the Company\x92s\nclinically proven PEACOCK', u'\xae', u', CORVUS', u'\xae', u' (our proprietary\ntreatment planning software), BAT', u'\xae', u' and ancillary treatment solutions. Please visit www.nasmedical.com for\nmore information.', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='',FILE='C:\\JMS\\eudelhofen\\04-10829-1\\task187972\\10829-1-mm.htm',USER='eudelho',CD='Sep 23 13:08 2004' ", u'\n', u'\n', u'\xa0', u'\n', u'S', u'tatements\nincluded in this release that are not historical facts may be considered\nforward-looking statements that are subject to a variety of risks and\nuncertainties. There are a number of important factors that could cause actual\nresults to differ materially from those expressed in any forward-looking\nstatements made by the Company including, but not limited to, uncertainties\nrelating to drug discovery and clinical development processes, the impact of\ncompetitive products and technological changes, changes in relationships with\nstrategic partners and dependence upon strategic partners for the performance\nof critical activities under collaborative agreements, the ability of the\nCompany to successfully directly market and sell its brachytherapy products,\nuncertainties relating to patent protection and regulatory approval, the stable\nsupply of appropriate isotopes, the impact of competitive products and pricing,\nresearch and development estimates, market opportunities, risks associated with\nstrategic opportunities or acquisitions the Company may pursue and the risk\nfactors included in the Company\x92s filings with the Securities and Exchange\nCommission. Any forward-looking statements contained in this news release speak\nonly as of the date of this release, and the Company undertakes no obligation\nto revise or update any forward-looking statements, whether as a result of new\ninformation, future results or otherwise.', u'\n', u'\xa0', u'\n', u'(\x97financial tables follow\x97)', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='',FILE='C:\\JMS\\eudelhofen\\04-10829-1\\task187972\\10829-1-mm.htm',USER='eudelho',CD='Sep 23 13:08 2004' ", u'\n', u'\n', u'\xa0', u'\n', u'NORTH\nAMERICAN SCIENTIFIC, INC.', u'\n', u'\xa0', u'\n', u'Consolidated\nBalance Sheets', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'July 31', u'\n  2004', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'October 31,', u'\n  2003', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(Unaudited)', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Current Assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Cash', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'232,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'1,761,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Marketable securities', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'14,481,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'32,587,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Accounts receivable', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'6,772,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2,167,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Inventories', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'6,529,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'692,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Income tax receivable', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'496,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Prepaid and other current assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,829,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,053,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Total current\n  assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'29,843,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'38,756,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Non-current\n  assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'8,362,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'14,767,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Equipment and leasehold improvements', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'4,315,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2,996,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Goodwill', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'22,932,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,866,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Intangible assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'27,426,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'813,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Other assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'122,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,334,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Total assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'93,000,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'62,532,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Liabilities and Stockholders\x92 Equity', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Current liabilities', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Accounts payable', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'5,196,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'1,620,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Accrued expenses', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'7,020,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'5,166,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Deferred revenue', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'5,786,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Total current liabilities', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'18,002,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'6,786,0000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Commitments and contingencies', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Stockholders\x92 Equity', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Preferred stock', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Common stock', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'166,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'103,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Additional paid-in capital', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'120,818,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'74,343,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Treasury stock, at cost \x96 19,000 shares', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(129,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(129,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'Accumulated deficit', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(45,857,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(18,571,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'Total stockholders\x92 equity', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'74,998,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'55,746,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Total liabilities and stockholders\x92 equity', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'93,000,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'62,532,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='',FILE='C:\\JMS\\eudelhofen\\04-10829-1\\task187972\\10829-1-mm.htm',USER='eudelho',CD='Sep 23 13:08 2004' ", u'\n', u'\n', u'\xa0', u'\n', u'NORTH AMERICAN\nSCIENTIFIC, INC.', u'\n', u'\xa0', u'\n', u'Consolidated Statements\nof Operations', u'\n', u'(Unaudited)', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Three months ended July 31,', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Nine months ended July 31,', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2004', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2003', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2004', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2003', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Net Sales', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'8,137,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'3,011,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'14,982,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'11,056,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Cost of goods sold', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'4,801,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,733,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'8,639,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'4,988,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Gross profit', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,336,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,278,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'6,343,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'6,068,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Selling expenses', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2,273,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'889,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,919,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2,463,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'General and administrative expenses', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,817,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,815,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'9,602,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'5,686,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Research and development', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,269,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,661,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'7,060,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'5,431,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'In-process research and development', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'7,800,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'7,800,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Impairment of long-lived assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'4,681,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'4,681,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Integration', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,056,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,056,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Loss from operations', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(19,560,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(3,087,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(27,775,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(7,512,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Interest and other income, net', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'114,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'250,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'489,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,534,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Loss before provision for income taxes', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(19,446,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(2,837,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(27,286,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(5,978,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Provision for income taxes', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Loss before cumulative effect of change in\n  accounting principle', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(19,446,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(2,837,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(27,286,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(5,978,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Cumulative effect of change in accounting\n  principle', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'311,000', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Net loss', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(19,446,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(2,837,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(27,286,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(6,289,000', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Basic and diluted loss per share:', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Loss before cumulative effect of change in\n  accounting principle', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(1.24', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(0.28', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(2.24', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(0.58', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Cumulative effect of change in accounting\n  principle', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(0.03', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'Net loss', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(1.24', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(0.28', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(2.24', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(0.61', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Shares used in per share calculations:', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Basic and diluted', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'15,679,214', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'10,259,002', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'12,193,057', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'10,252,661', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'###', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='',FILE='C:\\JMS\\eudelhofen\\04-10829-1\\task187972\\10829-1-mm.htm',USER='eudelho',CD='Sep 23 13:08 2004' ", u'\n', u'\n', u'\n', u'\n', u'GRAPHIC\n', u'3\n', u'g108291mmimage002.gif\n', u'GRAPHIC\n', u'\nbegin 644 g108291mmimage002.gif\nM1TE&.#EA=`%(`\'5P$"`P+_A(^IR^T/HSRB6CNSWKS[\nM/UT"2);FB::1>*GN"\\G^C^/5@,2B(B8\nM^".R9:CX"!E)PM)((WF)F5E)V&6I^0D:Q]E$F8*1X*@@QWCB.', u'SH4);$D/[', u'!KOR+"UMEY.\\*!QO@$E\nM+*S-?#!:[&S]%E^:\'8EU@\nMC`/*6*21\']KX7I`@WK6CB11VQ:.*%2(XD(LM2+G?CI&!]0.*VH7PW.EFC\nM6!`FV*.73!:8))LS)GB=EQVR62.6358I6(Q1', u'GDCF>V::@]1$V)Z&)-AEH\nM>P^.JEZ#JF=8@KKGK8NJ:>HK.YJ*J_$:AHLIR?_>OJK:[A"JNMDV#$3\nMZ;.RJFCIG\\9*6VL^.":;(KC:0:LM)5S:HAMI;KY6G;7BIEFNH_2!.', u'UY32RLAHS_:2.J>ZLF%4VB_S3T@G#Z;2\'6`&+\nMJC8;#]SPLB^+S#;4&+_[Z&$,`NWJRJ\\XC,)NBRBW[A\'K+6&@T=V&0GCAAA^.\nM>.**+\\YXXXX_#GGD:JCI0`"6_ULNP>6:)[`Y`)I__KD!F&', u'NFF8WZYZ*>G\nM[CGK#90NN>&4,P![Y:L?T/GJN8\\.@>Z^!]`Z\\,\'?/OSKQ,?^R>P*\'(_`[ZBS\nM[KSJO-ONO.G!2T]\\YYQ\'CWPFRC?O^O7@AXY[Z+L+_P#YU*.__/3;"Z\\][>$/\nM\'S[HW7OOX_@+3!___L^//C_Y]:]][M.?`+&7OOH-[!0H0?@7T\nMG_HLR+[W&8^"%1P?^B[8P!!N((`$S&`"`=A!#9*P?"E', u'\nM"4UX0PA&D(,;Q*$.+8C`]06QAD0D70K%EX\'S1,N/YB7F:96^-PC\\CZY42@4```[\n`\nend\n\n', u'\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']